Trial Outcomes & Findings for Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (NCT NCT05014568)

NCT ID: NCT05014568

Last Updated: 2025-09-04

Results Overview

The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. Statistics are based on 100 imputed datasets.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

407 participants

Primary outcome timeframe

Baseline to Week 8

Results posted on

2025-09-04

Participant Flow

Participants from the main study (DMVT-505-3101) had the option to participate in the open label extension study (DMVT-505-3103, NCT05142774).

Participant milestones

Participant milestones
Measure
Tapinarof Cream
tapinarof cream, 1%, applied topically once daily tapinarof cream, 1%: applied topically once daily
Vehicle Cream
vehicle cream, applied topically once daily Vehicle cream: applied topically once daily
Overall Study
STARTED
270
137
Overall Study
COMPLETED
238
110
Overall Study
NOT COMPLETED
32
27

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Tapinarof Cream
n=270 Participants
tapinarof cream, 1%, applied topically once daily tapinarof cream, 1%: applied topically once daily
Vehicle Cream
n=137 Participants
vehicle cream, applied topically once daily Vehicle cream: applied topically once daily
Total
n=407 Participants
Total of all reporting groups
Age, Continuous
15.6 years
STANDARD_DEVIATION 16.62 • n=5 Participants
15.6 years
STANDARD_DEVIATION 16.49 • n=7 Participants
15.6 years
STANDARD_DEVIATION 16.56 • n=5 Participants
Age, Customized
2-6 Years
76 Participants
n=5 Participants
39 Participants
n=7 Participants
115 Participants
n=5 Participants
Age, Customized
7-11 Years
75 Participants
n=5 Participants
37 Participants
n=7 Participants
112 Participants
n=5 Participants
Age, Customized
12-17 Years
67 Participants
n=5 Participants
34 Participants
n=7 Participants
101 Participants
n=5 Participants
Age, Customized
≥ 18 Years
52 Participants
n=5 Participants
27 Participants
n=7 Participants
79 Participants
n=5 Participants
Sex: Female, Male
Female
140 Participants
n=5 Participants
71 Participants
n=7 Participants
211 Participants
n=5 Participants
Sex: Female, Male
Male
130 Participants
n=5 Participants
66 Participants
n=7 Participants
196 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
54 Participants
n=5 Participants
44 Participants
n=7 Participants
98 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
212 Participants
n=5 Participants
92 Participants
n=7 Participants
304 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
4 Participants
n=5 Participants
1 Participants
n=7 Participants
5 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants
n=5 Participants
0 Participants
n=7 Participants
2 Participants
n=5 Participants
Race (NIH/OMB)
Asian
26 Participants
n=5 Participants
10 Participants
n=7 Participants
36 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
70 Participants
n=5 Participants
38 Participants
n=7 Participants
108 Participants
n=5 Participants
Race (NIH/OMB)
White
152 Participants
n=5 Participants
79 Participants
n=7 Participants
231 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
14 Participants
n=5 Participants
5 Participants
n=7 Participants
19 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
6 Participants
n=5 Participants
5 Participants
n=7 Participants
11 Participants
n=5 Participants
Region of Enrollment
Canada
40 Count of participants
n=5 Participants
12 Count of participants
n=7 Participants
52 Count of participants
n=5 Participants
Region of Enrollment
United States
230 Count of participants
n=5 Participants
125 Count of participants
n=7 Participants
355 Count of participants
n=5 Participants
Validated Investigator Global Assessment for Atopic Dermatitis
0 - Clear
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Validated Investigator Global Assessment for Atopic Dermatitis
1 - Almost Clear
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Validated Investigator Global Assessment for Atopic Dermatitis
2 - Mild
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Validated Investigator Global Assessment for Atopic Dermatitis
3 - Moderate
244 Participants
n=5 Participants
122 Participants
n=7 Participants
366 Participants
n=5 Participants
Validated Investigator Global Assessment for Atopic Dermatitis
4 - Severe
26 Participants
n=5 Participants
15 Participants
n=7 Participants
41 Participants
n=5 Participants
Percent Body Surface Area (BSA)
16.45 Percentage of Affected BSA
STANDARD_DEVIATION 8.666 • n=5 Participants
17.71 Percentage of Affected BSA
STANDARD_DEVIATION 9.500 • n=7 Participants
16.87 Percentage of Affected BSA
STANDARD_DEVIATION 8.964 • n=5 Participants
Eczema Area and Severity Index (EASI)
12.24 units on a scale
STANDARD_DEVIATION 5.007 • n=5 Participants
12.86 units on a scale
STANDARD_DEVIATION 5.633 • n=7 Participants
12.45 units on a scale
STANDARD_DEVIATION 5.228 • n=5 Participants

PRIMARY outcome

Timeframe: Baseline to Week 8

Population: ITT Population (MI Estimand)

The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. Statistics are based on 100 imputed datasets.

Outcome measures

Outcome measures
Measure
Tapinarof Cream
n=270 Participants
tapinarof cream, 1%, applied topically once daily tapinarof cream, 1%: applied topically once daily
Vehicle Cream
n=137 Participants
vehicle cream, applied topically once daily Vehicle cream: applied topically once daily
Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
45.4 Percentage of participants
13.9 Percentage of participants

SECONDARY outcome

Timeframe: Baseline to Week 8

Population: ITT Population (MI Estimand)

The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.

Outcome measures

Outcome measures
Measure
Tapinarof Cream
n=270 Participants
tapinarof cream, 1%, applied topically once daily tapinarof cream, 1%: applied topically once daily
Vehicle Cream
n=137 Participants
vehicle cream, applied topically once daily Vehicle cream: applied topically once daily
Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
55.8 Percentage of participants
22.9 Percentage of participants

SECONDARY outcome

Timeframe: Baseline to Week 8

Population: ITT Population (MI Estimand)

Assessment of percent body surface area (%BSA) is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% \[10 handprints\], upper extremities = 20% \[20 handprints\], trunk (including axillae and groin) = 30% \[30 handprints\], lower extremities, including buttocks, = 40% \[40 handprints\]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Outcome measures

Outcome measures
Measure
Tapinarof Cream
n=270 Participants
tapinarof cream, 1%, applied topically once daily tapinarof cream, 1%: applied topically once daily
Vehicle Cream
n=137 Participants
vehicle cream, applied topically once daily Vehicle cream: applied topically once daily
Mean Change in in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 8.
-10.11 change in affected BSA percentage
Standard Error 0.527
-4.47 change in affected BSA percentage
Standard Error 0.654

SECONDARY outcome

Timeframe: Baseline to Week 8

Population: ITT Population (MI Estimand)

The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.

Outcome measures

Outcome measures
Measure
Tapinarof Cream
n=270 Participants
tapinarof cream, 1%, applied topically once daily tapinarof cream, 1%: applied topically once daily
Vehicle Cream
n=137 Participants
vehicle cream, applied topically once daily Vehicle cream: applied topically once daily
Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
29.8 Percentage of participants
6.1 Percentage of participants

SECONDARY outcome

Timeframe: Baseline to Week 8

Population: ITT Population (MI Estimand) - subjects ≥ 12 years old with a Baseline PP-NRS score ≥ 4

The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week. Statistics are based on 100 imputed datasets.

Outcome measures

Outcome measures
Measure
Tapinarof Cream
n=103 Participants
tapinarof cream, 1%, applied topically once daily tapinarof cream, 1%: applied topically once daily
Vehicle Cream
n=54 Participants
vehicle cream, applied topically once daily Vehicle cream: applied topically once daily
Percent of Subjects ≥ 12 Years Old With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the Average Weekly PP-NRS From Baseline to Week 8.
55.8 Percentage of participants
34.2 Percentage of participants

Adverse Events

Tapinarof Cream

Serious events: 3 serious events
Other events: 118 other events
Deaths: 0 deaths

Vehicle Cream

Serious events: 0 serious events
Other events: 33 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Tapinarof Cream
n=270 participants at risk
tapinarof cream, 1%, applied topically once daily tapinarof cream, 1%: applied topically once daily
Vehicle Cream
n=137 participants at risk
vehicle cream, applied topically once daily Vehicle cream: applied topically once daily
Gastrointestinal disorders
Abdominal pain
0.37%
1/270 • Number of events 1 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Immune system disorders
Anaphylactic Shock
0.37%
1/270 • Number of events 1 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Infections and infestations
Arthritis bacterial
0.37%
1/270 • Number of events 1 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks

Other adverse events

Other adverse events
Measure
Tapinarof Cream
n=270 participants at risk
tapinarof cream, 1%, applied topically once daily tapinarof cream, 1%: applied topically once daily
Vehicle Cream
n=137 participants at risk
vehicle cream, applied topically once daily Vehicle cream: applied topically once daily
Gastrointestinal disorders
Vomiting
3.7%
10/270 • Number of events 15 • Through study completion, up to 9 weeks
0.73%
1/137 • Number of events 1 • Through study completion, up to 9 weeks
Gastrointestinal disorders
Abdominal pain
1.5%
4/270 • Number of events 4 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Gastrointestinal disorders
Diarrhoea
1.1%
3/270 • Number of events 3 • Through study completion, up to 9 weeks
0.73%
1/137 • Number of events 1 • Through study completion, up to 9 weeks
Gastrointestinal disorders
Nausea
0.37%
1/270 • Number of events 1 • Through study completion, up to 9 weeks
1.5%
2/137 • Number of events 2 • Through study completion, up to 9 weeks
General disorders
Pyrexia
1.9%
5/270 • Number of events 5 • Through study completion, up to 9 weeks
2.2%
3/137 • Number of events 3 • Through study completion, up to 9 weeks
General disorders
Application site pain
1.1%
3/270 • Number of events 4 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Infections and infestations
Folliculitis
8.1%
22/270 • Number of events 22 • Through study completion, up to 9 weeks
0.73%
1/137 • Number of events 1 • Through study completion, up to 9 weeks
Infections and infestations
Nasopharyngitis
4.8%
13/270 • Number of events 13 • Through study completion, up to 9 weeks
5.1%
7/137 • Number of events 7 • Through study completion, up to 9 weeks
Infections and infestations
Upper respiratory tract infection
4.8%
13/270 • Number of events 13 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Infections and infestations
COVID-19
2.6%
7/270 • Number of events 7 • Through study completion, up to 9 weeks
3.6%
5/137 • Number of events 5 • Through study completion, up to 9 weeks
Infections and infestations
Influenza
2.2%
6/270 • Number of events 6 • Through study completion, up to 9 weeks
0.73%
1/137 • Number of events 1 • Through study completion, up to 9 weeks
Infections and infestations
Application site folliculitis
1.1%
3/270 • Number of events 3 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Infections and infestations
Gastroenteritis viral
1.1%
3/270 • Number of events 3 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Infections and infestations
Pharyngitis streptococcal
1.1%
3/270 • Number of events 3 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Infections and infestations
Sinusitis
1.1%
3/270 • Number of events 3 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Musculoskeletal and connective tissue disorders
Pain in extremity
1.5%
4/270 • Number of events 5 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Musculoskeletal and connective tissue disorders
Myalgia
1.1%
3/270 • Number of events 3 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skim papilloma
1.1%
3/270 • Number of events 3 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Nervous system disorders
Headache
7.0%
19/270 • Number of events 20 • Through study completion, up to 9 weeks
2.2%
3/137 • Number of events 3 • Through study completion, up to 9 weeks
Respiratory, thoracic and mediastinal disorders
Asthma
2.2%
6/270 • Number of events 6 • Through study completion, up to 9 weeks
0.73%
1/137 • Number of events 1 • Through study completion, up to 9 weeks
Respiratory, thoracic and mediastinal disorders
Cough
1.5%
4/270 • Number of events 4 • Through study completion, up to 9 weeks
0.73%
1/137 • Number of events 1 • Through study completion, up to 9 weeks
Respiratory, thoracic and mediastinal disorders
Nasal congestion
1.1%
3/270 • Number of events 3 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Skin and subcutaneous tissue disorders
Dermatitis contact
1.5%
4/270 • Number of events 4 • Through study completion, up to 9 weeks
2.2%
3/137 • Number of events 3 • Through study completion, up to 9 weeks
Skin and subcutaneous tissue disorders
Urticaria
1.5%
4/270 • Number of events 4 • Through study completion, up to 9 weeks
1.5%
2/137 • Number of events 2 • Through study completion, up to 9 weeks
Skin and subcutaneous tissue disorders
Pruritus
1.1%
3/270 • Number of events 3 • Through study completion, up to 9 weeks
0.00%
0/137 • Through study completion, up to 9 weeks
Skin and subcutaneous tissue disorders
Dermatitis atopic
0.37%
1/270 • Number of events 1 • Through study completion, up to 9 weeks
2.2%
3/137 • Number of events 3 • Through study completion, up to 9 weeks

Additional Information

Clinical Lead, Late-Stage Clinical Development

Organon and Co

Phone: 551-430-6000

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place